Your browser doesn't support javascript.
loading
Safety and Efficacy of CYP2C19 Genotype-Guided Escalation of P2Y12 Inhibitor Therapy After Percutaneous Coronary Intervention in Chronic Kidney Disease: a Post Hoc Analysis of the TAILOR-PCI Study.
Mathew, Roy O; Sidhu, Mandeep S; Rihal, Charanjit S; Lennon, Ryan; El-Hajjar, Mohammed; Yager, Neil; Lyubarova, Radmila; Abdul-Nour, Khaled; Weitz, Steven; O'Cochlain, D Fearghas; Murthy, Vishakantha; Levisay, Justin; Marzo, Kevin; Graham, John; Dzavik, Vlad; So, Derek; Goodman, Shaun; Rosenberg, Yves D; Pereira, Naveen; Farkouh, Michael E.
Afiliação
  • Mathew RO; Department of Medicine, Loma Linda VA Health Care System, 11201 Benton Street, Loma Linda, CA, 92357, USA. Roy.mathew@va.gov.
  • Sidhu MS; Department of Medicine, Albany Medical College, 43 New Scotland Avenue Albany, Schenectady, NY, 12208, USA. mssidhu@yahoo.com.
  • Rihal CS; Department of Medicine, Mayo Clinic, Rochester, MN, USA.
  • Lennon R; Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN, USA.
  • El-Hajjar M; Department of Medicine, Albany Medical College, 43 New Scotland Avenue Albany, Schenectady, NY, 12208, USA.
  • Yager N; Department of Medicine, Albany Medical College, 43 New Scotland Avenue Albany, Schenectady, NY, 12208, USA.
  • Lyubarova R; Department of Medicine, Albany Medical College, 43 New Scotland Avenue Albany, Schenectady, NY, 12208, USA.
  • Abdul-Nour K; Henry Ford Health System, Detroit, MI, USA.
  • Weitz S; Cardiology Associates of Schenectady, Schenectady, NY, USA.
  • O'Cochlain DF; Department of Medicine, May Clinic Health System, Eau Claire, WI, USA.
  • Murthy V; Department of Endocrine and Cardiovascular Diseases, Mayo Clinic, Rochester, MN, USA.
  • Levisay J; Department of Medicine, North Shore University Health System, Evanston, IL, USA.
  • Marzo K; Department of Medicine, Winthrop University Hospital, Mineola, NY, USA.
  • Graham J; Department of Medicine, St. Michael's Hospital, Toronto, ON, Canada.
  • Dzavik V; Department of Medicine, University Health Network-Toronto General Hospital, Toronto, ON, Canada.
  • So D; Department of Medicine, University of Ottawa Heart Institute, Ottawa, ON, Canada.
  • Goodman S; Department of Medicine, St. Michael's Hospital, Toronto, ON, Canada.
  • Rosenberg YD; National Heart Lung and Blood Institute, Bethesda, MD, USA.
  • Pereira N; Department of Medicine, Mayo Clinic, Rochester, MN, USA.
  • Farkouh ME; Department of Medicine, University Health Network-Toronto General Hospital, Toronto, ON, Canada.
Cardiovasc Drugs Ther ; 2022 Nov 29.
Article em En | MEDLINE | ID: mdl-36445624
Palavras-chave
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Contexto em Saúde: 6_ODS3_enfermedades_notrasmisibles Problema de saúde: 6_chronic_kidney_disease / 6_kidney_renal_pelvis_ureter_cancer Tipo de estudo: Clinical_trials / Risk_factors_studies Idioma: En Revista: Cardiovasc Drugs Ther Assunto da revista: ANGIOLOGIA / CARDIOLOGIA / TERAPIA POR MEDICAMENTOS Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Estados Unidos
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Contexto em Saúde: 6_ODS3_enfermedades_notrasmisibles Problema de saúde: 6_chronic_kidney_disease / 6_kidney_renal_pelvis_ureter_cancer Tipo de estudo: Clinical_trials / Risk_factors_studies Idioma: En Revista: Cardiovasc Drugs Ther Assunto da revista: ANGIOLOGIA / CARDIOLOGIA / TERAPIA POR MEDICAMENTOS Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Estados Unidos